Michael Salib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Salib has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Ibrahim Mohamed
Alexandria University, Faculty of Medicine, Alexandria, Egypt
3 shared publications - Mona Nada
Cairo University
3 shared publications - Aya K. Hegazy
Alexandria University
1 shared publication - Basmalla Ashraf
Alexandria University
1 shared publication Hagar W. Amer
Alexandria University
1 shared publication- Masa I. Halwag
Faculty of Medicine, Alexandria University, Alexandria, Al Attarin, Egypt
1 shared publication
Latest Publications
- Open Access
- 26 July 2026
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 9
Status migrainosus in children and adolescents: A systematic literature review of demographic and clinical characteristics, precipitating factors, prognosis, treatments, and response
Background: Status migrainosus (SM) is a prolonged migraine attack lasting over 72 hours. Pediatric-specific data on SM remain sparse. Methods: Searches were conducted in six medical databases to July 2025. Eligible studies included clinical trials, cohorts, and case series (≥5 patients) reporting SM. Independent reviewers conducted screening, extraction, and quality appraisal. Results: Of 658 studies, 17 ( n = 7161;1857 pediatric SM cases) were included—predominantly single-center, retrospective studies, without randomized controlled trials. Most SM cohorts showed a female, adolescent (13–16 years) preponderance. SM's management strategies were heterogeneous; with peripheral nerve (PNB) and sphenopalatine ganglion (SPG) blocking procedures (3 studies, 690 patients) and anti-seizure medications (2 studies using valproate, 146 patients) being commonly reported. PNB and SPG blocking procedures were associated with short-term improvement and safety. In one comparative study of 94 patients, lidocaine infusions showed a trend toward faster pain relief and fewer adverse effects than IV valproate. One study of 177 patients directly compared IV dihydroergotamine to PNB, identifying a longer hospital duration of stay among dihydroergotamine recipients but a better response rate. Factors associated with poor response included older age, anxiety, medication overuse, and baseline severity. Among others, self-reported psychological stress was an SM trigger in two studies. Interpretation: Available evidence on SM in pediatric populations remains limited by non-randomized evidence, prone to inherent bias. Consequently, multicenter, comparative, randomized trials are warranted to establish pediatric-specific protocols. Observational evidence suggests that PNB/SPG blocking procedures may offer promise to those with failure of medical management strategies. Trial Registration: This PRISMA-compliant review was prospectively registered on PROSPERO (CRD420251088970).
- 26 July 2026
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 9
Open AccessStatus migrainosus in children and adolescents: A systematic literature review of demographic and clinical characteristics, precipitating factors, prognosis, treatments, and response
Background: Status migrainosus (SM) is a prolonged migraine attack lasting over 72 hours. Pediatric-specific data on SM remain sparse. Methods: Searches were conducted in six medical databases to July 2025. Eligible studies included clinical trials, cohorts, and case series (≥5 patients) reporting SM. Independent reviewers conducted screening, extraction, and quality appraisal. Results: Of 658 studies, 17 ( n = 7161;1857 pediatric SM cases) were included—predominantly single-center, retrospective studies, without randomized controlled trials. Most SM cohorts showed a female, adolescent (13–16 years) preponderance. SM's management strategies were heterogeneous; with peripheral nerve (PNB) and sphenopalatine ganglion (SPG) blocking procedures (3 studies, 690 patients) and anti-seizure medications (2 studies using valproate, 146 patients) being commonly reported. PNB and SPG blocking procedures were associated with short-term improvement and safety. In one comparative study of 94 patients, lidocaine infusions showed a trend toward faster pain relief and fewer adverse effects than IV valproate. One study of 177 patients directly compared IV dihydroergotamine to PNB, identifying a longer hospital duration of stay among dihydroergotamine recipients but a better response rate. Factors associated with poor response included older age, anxiety, medication overuse, and baseline severity. Among others, self-reported psychological stress was an SM trigger in two studies. Interpretation: Available evidence on SM in pediatric populations remains limited by non-randomized evidence, prone to inherent bias. Consequently, multicenter, comparative, randomized trials are warranted to establish pediatric-specific protocols. Observational evidence suggests that PNB/SPG blocking procedures may offer promise to those with failure of medical management strategies. Trial Registration: This PRISMA-compliant review was prospectively registered on PROSPERO (CRD420251088970).
- Open Access
- 15 April 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1) , 107
Migraine as a risk factor for retinal vascular events and maculopathies: a systematic review and meta-analysis of 47 million individuals
Background: Migraine is increasingly recognized as a systemic disorder associated with cerebrovascular disease, endothelial dysfunction, and microvascular retinal changes. Given shared features between the retina and cerebral circulation, retinal vascular events (RVEs) and maculopathies may represent additional vascular manifestations of migraine. We aim to meta-analyze evidence on RVE and maculopathy risk in migraine. Methods: We conducted a PRISMA-compliant systematic review and meta-analysis (PROSPERO: CRD420251250431). Web of Science, PubMed, Scopus, and meeting abstracts were searched through January 2026, without language or date restrictions. Observational studies comparing the risk of RVEs or maculopathies in migraineurs versus non-migraineurs were included. Random-effects meta-analyses were performed using pooled risk ratios (RRs) from best adjusted analyses with 95% confidence intervals (CIs). Study quality was assessed using the Newcastle–Ottawa Scale. Results: Thirteen studies encompassing 47,042,175 individuals met the inclusion criteria. An adjusted analysis suggested migraine was associated with a significantly increased risk of any RVE (RR 2.04, 95% CI 1.53–2.72). Migraineurs demonstrated elevated risks of any RAO (RR 2.12, 95% CI 1.25–3.60), central RAO (RR 1.62, 95% CI 1.14–2.30), and branch RAO (RR 1.94, 95% CI 1.57–2.40). Similarly, the risk of any RVO was increased (RR 1.72, 95% CI 1.44–2.04), including central and branch forms. Migraine with aura conferred a higher arterial occlusion risk compared to migraine without aura in two studies. Evidence on the protective effects of therapies remains inconclusive. Three studies suggest associations with neovascular age-related macular degeneration and central serous chorioretinopathy. Ten studies were rated as good according to the AHRQ standards. Conclusions: Migraine is associated with a significantly increased risk of retinal arterial and venous occlusive events, yet current literature is limited by miscoding from administrative database studies. Evidence on increased maculopathy risk in migraine remains elusive. These results support heightened awareness of retinal vascular complications in migraineurs and proactive ocular monitoring, particularly those with aura. Past links implying higher stroke risk following RAO, combined with migraine’s established association with stroke, hint at the need for primary stroke prevention in migraineurs with RAO. Prospective studies to clarify causality and the impact of migraine therapies - particularly anti-CGRPs - on retinal vascular risk are warranted.
- 15 April 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1) , 107
Open AccessMigraine as a risk factor for retinal vascular events and maculopathies: a systematic review and meta-analysis of 47 million individuals
Background: Migraine is increasingly recognized as a systemic disorder associated with cerebrovascular disease, endothelial dysfunction, and microvascular retinal changes. Given shared features between the retina and cerebral circulation, retinal vascular events (RVEs) and maculopathies may represent additional vascular manifestations of migraine. We aim to meta-analyze evidence on RVE and maculopathy risk in migraine. Methods: We conducted a PRISMA-compliant systematic review and meta-analysis (PROSPERO: CRD420251250431). Web of Science, PubMed, Scopus, and meeting abstracts were searched through January 2026, without language or date restrictions. Observational studies comparing the risk of RVEs or maculopathies in migraineurs versus non-migraineurs were included. Random-effects meta-analyses were performed using pooled risk ratios (RRs) from best adjusted analyses with 95% confidence intervals (CIs). Study quality was assessed using the Newcastle–Ottawa Scale. Results: Thirteen studies encompassing 47,042,175 individuals met the inclusion criteria. An adjusted analysis suggested migraine was associated with a significantly increased risk of any RVE (RR 2.04, 95% CI 1.53–2.72). Migraineurs demonstrated elevated risks of any RAO (RR 2.12, 95% CI 1.25–3.60), central RAO (RR 1.62, 95% CI 1.14–2.30), and branch RAO (RR 1.94, 95% CI 1.57–2.40). Similarly, the risk of any RVO was increased (RR 1.72, 95% CI 1.44–2.04), including central and branch forms. Migraine with aura conferred a higher arterial occlusion risk compared to migraine without aura in two studies. Evidence on the protective effects of therapies remains inconclusive. Three studies suggest associations with neovascular age-related macular degeneration and central serous chorioretinopathy. Ten studies were rated as good according to the AHRQ standards. Conclusions: Migraine is associated with a significantly increased risk of retinal arterial and venous occlusive events, yet current literature is limited by miscoding from administrative database studies. Evidence on increased maculopathy risk in migraine remains elusive. These results support heightened awareness of retinal vascular complications in migraineurs and proactive ocular monitoring, particularly those with aura. Past links implying higher stroke risk following RAO, combined with migraine’s established association with stroke, hint at the need for primary stroke prevention in migraineurs with RAO. Prospective studies to clarify causality and the impact of migraine therapies - particularly anti-CGRPs - on retinal vascular risk are warranted.
- Open Access
- 13 November 2025
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 26 (1) , 259
Migraine and pregnancy-related headaches as a risk factor for cardiovascular and cerebrovascular events in pregnancy: a systematic review and meta-analysis of over 94 million pregnancies
Background: Migraine is prevalent among women of childbearing age and is associated with increased long-term cardiovascular and cerebrovascular risk. Pregnancy, a hypercoagulable state, may potentiate these risks. This study aimed to quantify the association between migraine or pregnancy-related headaches and cerebrovascular and cardiovascular events during pregnancy and the postpartum period. Methods: We conducted a PRISMA-compliant systematic review and meta-analysis of observational studies comparing pregnant women with and without migraine or pregnancy-related headaches. PubMed, Scopus, and Web of Science were searched through May 8, 2025. Adjusted odds ratios (ORs) were pooled using random-effects models. Results: Twelve studies encompassing 94,195,776 pregnancies met the inclusion criteria. Migraine was associated with markedly increased odds of all strokes and transient ischemic attacks (OR 10.45; 95% CI 4.27–25.57) and ischemic stroke (OR 7.14; 95% CI 2.51–20.31). Hemorrhagic stroke risk was elevated but not statistically significant overall (OR 2.25; 95% CI 0.99–5.18), while subarachnoid hemorrhage showed a 69% increased odds. Regarding cardiovascular events: myocardial infarction risk increased by 96%, peripartum cardiomyopathy odds were 2.68-fold (95% CI 1.73–4.14), and spontaneous coronary artery dissection odds were 9.21-fold higher (95% CI 3.72–22.82). All included studies were rated as “good” quality by the Newcastle-Ottawa Scale. Conclusions: Migraine and pregnancy-related headaches are independent risk factors for a broad spectrum of cerebrovascular and cardiovascular events during pregnancy and the puerperium. These findings highlight the need for heightened clinical surveillance, targeted cardiovascular risk counselling, and multidisciplinary management strategies for this population.
- 13 November 2025
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 26 (1) , 259
Open AccessMigraine and pregnancy-related headaches as a risk factor for cardiovascular and cerebrovascular events in pregnancy: a systematic review and meta-analysis of over 94 million pregnancies
Background: Migraine is prevalent among women of childbearing age and is associated with increased long-term cardiovascular and cerebrovascular risk. Pregnancy, a hypercoagulable state, may potentiate these risks. This study aimed to quantify the association between migraine or pregnancy-related headaches and cerebrovascular and cardiovascular events during pregnancy and the postpartum period. Methods: We conducted a PRISMA-compliant systematic review and meta-analysis of observational studies comparing pregnant women with and without migraine or pregnancy-related headaches. PubMed, Scopus, and Web of Science were searched through May 8, 2025. Adjusted odds ratios (ORs) were pooled using random-effects models. Results: Twelve studies encompassing 94,195,776 pregnancies met the inclusion criteria. Migraine was associated with markedly increased odds of all strokes and transient ischemic attacks (OR 10.45; 95% CI 4.27–25.57) and ischemic stroke (OR 7.14; 95% CI 2.51–20.31). Hemorrhagic stroke risk was elevated but not statistically significant overall (OR 2.25; 95% CI 0.99–5.18), while subarachnoid hemorrhage showed a 69% increased odds. Regarding cardiovascular events: myocardial infarction risk increased by 96%, peripartum cardiomyopathy odds were 2.68-fold (95% CI 1.73–4.14), and spontaneous coronary artery dissection odds were 9.21-fold higher (95% CI 3.72–22.82). All included studies were rated as “good” quality by the Newcastle-Ottawa Scale. Conclusions: Migraine and pregnancy-related headaches are independent risk factors for a broad spectrum of cerebrovascular and cardiovascular events during pregnancy and the puerperium. These findings highlight the need for heightened clinical surveillance, targeted cardiovascular risk counselling, and multidisciplinary management strategies for this population.